%0 Journal Article
%A Wiese, M.
%A Schill, F.
%A Sturm, D.
%A Pfister, S.
%A Hulleman, E.
%A Johnsen, S. A.
%A Kramm, C. M.
%T No Significant Cytotoxic Effect of the EZH2 Inhibitor Tazemetostat (EPZ-6438) on Pediatric Glioma Cells with Wildtype Histone 3 or Mutated Histone 3.3.
%J Klinische Pädiatrie
%V 228
%N 3
%@ 1439-3824
%C Stuttgart
%I Thieme
%M DKFZ-2017-06011
%P 113 - 117
%D 2016
%X Glioblastoma multiforme (GBM) and diffuse intrinsic pontine glioma (DIPG) belong to the most aggressive cancers in children with poor prognosis and limited therapeutic options. Therapeutic targeting of epigenetic proteins may offer new treatment options. Preclinical studies identified Enhancer of Zeste Homolog 2 (EZH2) within polycomb repressor complex 2 (PRC2) as a potential epigenetic anti-tumor target in adult GBM cells but similar inhibition studies in pediatric GBM/DIPG were still missing. Moreover, approximately 30
%K Benzamides (NLM Chemicals)
%K EPZ-6438 (NLM Chemicals)
%K Histones (NLM Chemicals)
%K Pyridones (NLM Chemicals)
%K EZH2 protein, human (NLM Chemicals)
%K Enhancer of Zeste Homolog 2 Protein (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:27135271
%R 10.1055/s-0042-105292
%U https://inrepo02.dkfz.de/record/130935